Find in Library

S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH-RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-04

oleh: C. Touzeau, A. Perrrot, C. Hulin, S. Manier, M. Macro, M.-L. Chretien, L. Karlin, O. Decaux, C. Jacquet, M. Tiab, X. Leleu, L. Planchce, H. Avet-Loiseau, P. Moreau